<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04940546</url>
  </required_header>
  <id_info>
    <org_study_id>neoSXB-MSS-CRLM</org_study_id>
    <nct_id>NCT04940546</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients</brief_title>
  <official_title>Prospective Safety Study of Sintilimab Combined With XELOX Plus Bevacizumab for Preoperative Neoadjuvant Therapy of CRLM Patients With pMMR/MSS Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, single arm study aims to evaluate the preoperative neoadjuvant safety of&#xD;
      Sintilimab combined with XELOX plus bevacizumab in colorectal patients with liver metastasis&#xD;
      and pMMR/MSS status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      This preliminary prospective study aims to evaluate the safety of neoadjuvant treatment&#xD;
      combination of Sintilimab, XELOX and bevacizumab and also asses safety during surgery of&#xD;
      colorectal patients with liver metastasis and pMMR/MSS status.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      To evaluate Pathological Remission Rate (pCR/MPR/PR rate), Objective Response Rate (ORR),&#xD;
      Recurrence Free Survival (RFS) and Overall Survival (OS).&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      Analysis of liver metastasis before and after treatment to compare molecular and&#xD;
      immunophenotypic changes.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive Sintilimab + XELOX regimen every 3 weeks for 4 cycles and Bevacizumab every&#xD;
      3 weeks for 2 cycles. After which if there are no new lesions upon assessment, radical&#xD;
      surgery is performed within 6 weeks after neoadjuvant treatment. After surgery 4 cycles of&#xD;
      XELOX regimen is advised for adjuvant therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Number of patients with adverse events and severity according to NCICTCAE v5.0 during treatment period and using Clavien-Dindo classification of surgical complications for surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological Remission Rate</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Assessment of the absence of residual tumor pathologically</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Evaluation of changes in tumor size using the RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence Free Survival</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The length of time during and after the treatment of the disease, that a patient lives with the disease without recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The length of time from the start of treatment that patients diagnosed are still alive</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Sintilimab + XELOX + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Sintilimab + XELOX regimen every 3 weeks for 4 cycles and Bevacizumab every 3 weeks for 2 cycles.&#xD;
Details are as follows:&#xD;
Sintilimab: 200mg intravenously, d1 Oxaliplatin: 135mg/m2 intravenously, d1 Capecitabine: 2g/m2 orally, d1-14 for Bevacizumab: 7.5mg/kg intravenously, d1&#xD;
After neoadjuvant treatment, if there are no new lesions upon radiological and Multidisciplinary Team (MDT) assessment, radical surgery is performed within 6 weeks. If there are new lesions the surgical team will assess the optimal time for surgery.&#xD;
After surgery 4 cycles of XELOX regimen is advised for adjuvant therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Mode of administration: Intravenously</description>
    <arm_group_label>Sintilimab + XELOX + Bevacizumab</arm_group_label>
    <other_name>Anti-PD-1 monoclonal antibody IBI308</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Mode of administration: Intravenously</description>
    <arm_group_label>Sintilimab + XELOX + Bevacizumab</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Mode of administration: Orally</description>
    <arm_group_label>Sintilimab + XELOX + Bevacizumab</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Mode of administration: Intravenously</description>
    <arm_group_label>Sintilimab + XELOX + Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years old and ≤75 years old&#xD;
&#xD;
          -  Histologically confirmed colorectal adenocarcinoma&#xD;
&#xD;
          -  Radiologically and/or pathologically confirmed liver metastasis&#xD;
&#xD;
          -  Immunohistochemistry and/or genetic testing confirmed pMMR/MSS&#xD;
&#xD;
          -  Absence of extrahepatic metastasis confirmed by CT, MRI or PET/CT (if necessary)&#xD;
&#xD;
          -  Primary lesion has been or can be removed by radical surgery&#xD;
&#xD;
          -  Liver metastases can be resected (or using intraoperative radiofrequency) and is&#xD;
             expected to achieve tumor-free status (NED) after surgery. Resectable liver metastases&#xD;
             are defined explicitly as ① less than 5 metastatic lesions; ② R0 resection is&#xD;
             achievable by resection or intraoperative radiofrequency; ③ Remaining liver volume is&#xD;
             expected to be sufficient after surgery; ④ The following can be retained after&#xD;
             resection: One hepatic vein, preserve blood flow in and out of the remaining liver,&#xD;
             the bile duct, and at least 2 adjacent livers segments ⑤ There is no extrahepatic&#xD;
             metastasis.&#xD;
&#xD;
          -  Apart from surgical resection of the primary lesion, he/she has not received any&#xD;
             anti-tumor treatment for liver metastasis (including chemotherapy, targeted drugs,&#xD;
             interventional therapy, immunotherapy, radiotherapy, etc.)&#xD;
&#xD;
          -  Normal hematological function (platelets&gt;90×109/L; white blood cells&gt;3×109/L;&#xD;
             neutrophils&gt;1.5×109/L)&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.5 times the upper limit of normal (ULN), transaminase ≤ 5 times&#xD;
             ULN, alkaline phosphatase ≤2.5 ULN, No ascites, normal coagulation function, albumin&#xD;
             ≥35g/L&#xD;
&#xD;
          -  Child-Pugh classification of the liver is A&#xD;
&#xD;
          -  Serum creatinine is less than the upper limit of normal (ULN), or the calculated&#xD;
             creatinine clearance rate is greater than 50ml/min (using Cockcroft-Gault formula)&#xD;
&#xD;
          -  ECOG score 0-1&#xD;
&#xD;
          -  Life expectancy&gt; 3 months&#xD;
&#xD;
          -  Signed and written informed consent&#xD;
&#xD;
          -  Willing and able to follow up until death or the end of the study or the study is&#xD;
             terminated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of distant metastases outside the liver after the diagnosis of colorectal&#xD;
             cancer&#xD;
&#xD;
          -  Liver metastases have been treated with chemotherapy, targeted drugs, intervention,&#xD;
             immunotherapy, radiotherapy, etc.&#xD;
&#xD;
          -  No surgical resection plan for liver metastases&#xD;
&#xD;
          -  Received oxaliplatin-containing adjuvant chemotherapy in the past 1 year&#xD;
&#xD;
          -  Any residual toxicity from previous chemotherapy (except for hair loss), such as&#xD;
             peripheral neuropathy ≥NCI CTC v3.0 Grade 2&#xD;
&#xD;
          -  Use of immunosuppressive drugs within 1 week before treatment, not including nasal&#xD;
             sprays, inhalation or other local treatments, partial glucocorticoids or physiological&#xD;
             doses of systemic glucocorticoids (i.e. not more than 10 mg/day prednisone or&#xD;
             equivalent doses of other glucocorticoids) or use of corticoids to prevent contrast&#xD;
             agent allergy&#xD;
&#xD;
          -  Suffering from interstitial lung disease that requires steroid therapy&#xD;
&#xD;
          -  Medical history of active autoimmune disease that needs symptomatic treatment within&#xD;
             the past 2 years. Vitiligo, psoriasis, hair loss, or Grave's disease that do not&#xD;
             require systemic treatment within the past 2 years, or hypothyroidism patients that&#xD;
             only need thyroid hormone replacement therapy and type I diabetic patients requiring&#xD;
             only insulin replacement therapy can be enrolled&#xD;
&#xD;
          -  History of primary immunodeficiency&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Known history of allergies related to organ transplantation or hematopoietic stem cell&#xD;
             transplantation&#xD;
&#xD;
          -  Allergic to any monoclonal antibody or chemotherapeutic drug (fluorouracil,&#xD;
             oxaliplatin) and its ingredients&#xD;
&#xD;
          -  Have bleeding tendency or coagulopathy&#xD;
&#xD;
          -  Patients with apparent symptoms of intestinal obstruction&#xD;
&#xD;
          -  Hypertensive crisis or hypertensive encephalopathy&#xD;
&#xD;
          -  Serious uncontrollable systemic complications such as infection or diabetes&#xD;
&#xD;
          -  Clinically severe cardiovascular diseases such as cerebrovascular accident (within 6&#xD;
             months before enrollment), myocardial infarction (enrollment within the first 6&#xD;
             months), uncontrollable hypertension, unstable angina pectoris, heart failure (NYHA&#xD;
             2-4), arrhythmia requiring medical treatment&#xD;
&#xD;
          -  Presence of central nervous system disease ( such as primary brain tumor, history of&#xD;
             uncontrollable epilepsy, any brain metastases or stroke)&#xD;
&#xD;
          -  Suffered from other malignant tumors in the past 5 years (except resected skin basal&#xD;
             cell carcinoma and/or cervical carcinoma in situ)&#xD;
&#xD;
          -  Received any drug treatment used for this study in the last 28 days&#xD;
&#xD;
          -  Women who are pregnant and breastfeeding. Women of childbearing age who do not use or&#xD;
             refuse to use effective non-hormonal contraceptive methods (intrauterine contraceptive&#xD;
             ring, barrier contraception combined with spermicidal gel or female sterilization )&#xD;
             (&lt;2 years after the last menstruation) or men with childbearing potential who are&#xD;
             unable or unwilling to comply with the research protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuhong Li</last_name>
    <phone>87342487</phone>
    <phone_ext>020</phone_ext>
    <email>liyh@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Yuhong, MD</last_name>
      <phone>020-87342487</phone>
      <email>liyh@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Li Yuhong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yuhong Li</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Colorectal liver metastasis</keyword>
  <keyword>pMMR/MSS</keyword>
  <keyword>Sintilimab</keyword>
  <keyword>XELOX</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

